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utilization of prescription drug monitoring
programs
A survey study
Amie Goodin, PhD, MPPa,b,
∗
, Jungjun Bae, BSd, Chris Delcher, PhDc,d, Joshua Brown, PharmD, PhDa,b,
Dikea Roussos-Ross, MDe,f
Abstract
Query of Prescription DrugMonitoring Programs (PDMPs) is recommended before prescribing opioids by the USCenters for Disease
Control and Prevention, to inform clinical practice and aid diversion prevention. Many states mandate prescriber PDMP use;
however, little is known about PDMP perception of utility and use among Obstetricians-Gynecologists (OB/GYN), who are the
primary provider for most women during pregnancy.
This study examined OB/GYN perceptions and utilization of their state PDMP.
Survey items were developed by expert consensus. A voluntary anonymous survey was emailed to a random sample of 5000OB/
GYNs (adjusted participants n=1470, minus unread/refusals). Responses were stratified by state policy environment, where
response frequency distributions were compared for OB/GYNs practicing in states with mandatory vs voluntary PDMP query.
Adjusted response rate was 27% (n=397). Most OB/GYNs (78%) were registered with their PDMP. The majority agreed that “
. . . mandating physician use of the PDMP was a good idea” (51.4% mandatory state vs 58.3% voluntary state). Respondents in
mandatory states reported that the primary purpose of the PDMP was “to allow the physician to verify medications that the patient is
being prescribed” less frequently than those in voluntary states (38.3% vs 52.8%). Several report speaking with patients about
controlled substance prescriptions after viewing PDMP reports (27.8% in mandatory vs 26.3% in voluntary states). In qualitative
responses, reported frustration with PDMPs was evident.
OB/GYNs are diverse in their perceptions regarding the utility and purpose of PDMPs. Tailored education is needed regarding
clinical utility of PDMPs for OB/GYN practice.
Abbreviations: ACOG=American College of Obstetricians andGynecologists, ASAM= American Society of AddictionMedicine,
CDC = Centers for Disease Control and Prevention, OB/GYNs = Obstetricians-Gynecologists, PDMPs = Prescription Drug
Monitoring Programs.
Keywords: opioid abuse, opioid diversion, prescription drug monitoring programs, primary prevention tools, women’s health
1. Introduction
The US Centers for Disease Control and Prevention (CDC) issued
guidelines in 2016 recommending that clinicians review their
state Prescription Drug Monitoring Program (PDMP) data when
initiating and/or continuing opioid therapies under certain
clinical circumstances.[1] PDMPs provide opioid and other
controlled substance dispensing histories and other measures
to clinicians for patients in their care. The American College of
Obstetricians and Gynecologists (ACOG) and the American
Society of Addiction Medicine (ASAM) jointly released a
committee opinion to clarify recommendations for obstetri-
cian-gynecologists (OB/GYN) that treat patients who are
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prescribed or may use opioids during pregnancy, medically or
non-medically, following the release of the CDC guidelines.[2]
The ACOG-ASAM recommendations endorse OB/GYN usage of
PDMPs as a primary prevention tool for opioid-related adverse
events.
As of mid-2020, most states now a) mandate that all controlled
substance prescribers register with their state PDMP and b)
require all or certain prescribers to check the PDMP when
initiating controlled substance prescriptions, particularly for US
Drug Enforcement Agency (DEA) Schedule II opioids.[3]
Physician use of PDMPs increases when administrative registra-
tion with the state is mandated,[4] and prescribers reportedly
comply with PDMP usage mandates.[5] However, prescribers
across multiple specialties report that stand-alone PDMP data is
difficult to access and incorporate into their workflow.[6] For OB/
GYNs in particular, PDMPs are viewed as less effective, positive,
or useful when compared to other primary care physicians.[7] In
this literature, OB/GYNs sample sizes are low and they have
sometimes been categorized with “other” prescriber specialties [8]
making it difficult to understand their nuanced PDMP use and
perceptions. One study in Washington Medicaid reported that
OB/GYNs had the second lowest uptake in both PDMP
registration and usage when compared with other physician
specialties.[9]
Since OB/GYNs are the primary source of care for many
women and comprise the majority of care during pregnancy;[10–
12] they are well-positioned to provide screening and intervention
for opioid-related sequelae. The purpose of this study was to
assess OB/GYN utilization and perceptions of their state PDMP




A workgroup consisting of an OB/GYN, a pharmacist, and
health services researchers reviewed survey items from several
publicly available state-level PDMP survey instruments.[13]
Survey items from previously published instruments were
adapted for OB/GYNs to assess the perception of PDMP
effectiveness, knowledge of PDMP functions, and self-reported
use of PDMPs. The survey instrument was reviewed and
approved by the ACOG District XII Committee on Health Care
for Underserved Women prior to release and is available in
Supplementary Materials, http://links.lww.com/MD/F548.
2.2. Study design and protocol
The study design was a cross-sectional survey. The research team
partnered with ACOG leadership, who oversaw dissemination of
the survey link and accompanying study description and
explanation via email to a random sample of 5000 ACOG
members with an active license to practice in the United States in
May 2018. A reminder email was sent each week following the
initial email invitation for a period of 6 weeks and the survey link
remained active for a period of one week following the final
reminder in July 2018. Survey responses were anonymous, but
email read receipt data from the invitation were collected to
calculate an adjusted response rate. Data were collected in
Qualtrics (Qualtrics, Provo, Utah, USA). The University of
Florida Institutional Review Board reviewed and approved this
study.
2.3. Analysis
Response frequencies were calculated for each item and all surveys
with>1 item responsewere included in theanalysis (n=397). State
regulatory environment was classified as “mandatory” or
“voluntary” based on the legal requirements for PDMP query
(as of July 2018) and the physicians primary practice location. Chi
square analysis was used to compare differences in response
distribution between respondents practicing in mandatory versus
voluntary PDMP states. A priori significance was set at 0.05.
Qualitative and free-text survey itemswere analyzed and coded
for instances of similar thematic content by 3 reviewers, and, in
instances of disagreement, our OB/GYN acted as a fourth and
deciding vote. All analyses were conducted in Excel and SAS 9.4
(SAS Institute Inc., Cary, North Carolina, USA).[14,16]
3. Results
A total of n=1470 survey invitations were opened and read,
resulting in an adjusted response rate of 27% (n=397 surveys
completed). About a third of respondents were in private practice
settings, and few were still considered trainees (60.7% classified
as Attending).Most respondents practiced in amandatory PDMP
state (80.6%), 9.6% practiced in voluntary PDMP states, and
9.8% did not indicate their practice location. The majority were
currently registered with the PDMP (77.6%). To gauge OB/GYN
familiarity and understanding of PDMP data, respondents were
asked to identify what information is provided by the PDMP
from a list of options. Approximately, 30% were unaware that
the PDMP identifies the prescriber writing each prescription and
nearly half of respondents were unaware that the PDMP identifies
dispensing pharmacies. A summary of other respondent
characteristics is shown in Table 1.
Those practicing in mandatory versus voluntary states
perceived the primary purpose of PDMPs differently (Table 2)
and the majority of respondents suspected that 0 to 10% of their
patients misuse or abuse opioids (Fig. 1). In free-text responses
regarding the primary purpose of PDMPs, a majority of
respondents that selected “other” purpose expressed frustration
with PDMP usage and/or mandatory use laws (n=14, Table 2).
Three content themes of PDMP purpose emerged from these free-
text responses:
1. Increase in physician burden [sample response: “To burden
physicians with police work”],
2. Skepticism of government involvement [sample response:
“Government bull [expletive]”], and
3. Oversight of prescriber activity [sample response: “So that
state government and legislators can say they are doing
something about the “opioid crisis””].
Respondents report most frequently querying the PDMP for
patients that are currently using or prescribed opioids, and when
they treat patients suspected of drug abuse (Fig. 1). Respondents
most frequently report taking action as a result of using the
PDMP by confirming prescription fills (31.3% in mandatory
states; 23.7% in voluntary states), followed by speaking with
patients about controlled substance use (27.8% mandatory
states; 26.3% voluntary states). About 1 in 5 respondents
indicated they confirmed doctor shopping behaviors as a result of
querying the PDMP. No respondents reported referring patients
to law enforcement (0%) and Child Protective Services referrals
were also rare (1.9% in mandatory states; 0.0% in voluntary
states; Table 3).
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Overall, 53% of OB/GYNs agreed that “ . . . mandating
prescriber use of the PDMP was a good idea.” A
greater proportion (58.3%) of respondents practicing in
voluntary states agreed or strongly agreed with this statement
(Fig. 2).
4. Discussion
Our study is the largest to-date onOB/GYNperceptions anduse of
their state PDMPs, and is among the first to assess perception of
opioid use among the patients in their care. These findings suggest
that OB/GYN perceptions may be tied to experience with the
PDMP as evidenced by a significantly different stated purpose of
the PDMP when examined by practice legal environment. The
skepticism expressed by many respondents regarding PDMP
effectiveness as aprimaryprevention tool for several opioid-related
sequelae is concerning, despite recommendations. The findings
regarding PDMP utility as a primary prevention tool were
documented in a separate report analyzing these same data.[7]
A recent survey of ACOG Fellows and Junior Fellows reported
thatmostOB/GYNrespondents continue toprescribe opioids for a
variety of indications, but few reported adherence to opioid
prescribing guidelines.[15] In that ACOG survey, 81% of
respondents also reported that they were unaware that the
primary source of diverted opioids were prescriptions from friends
and family members.
4.1. Clinical and research implications
Many states have recently adopted legislation to restrict opioid
prescribing and dispensing by limiting quantities of outpatient
prescriptions of opioids for acute pain[16] and several other states
have similar legislation under consideration.[17] Additionally,
federal legislation has been proposed to limit new opioid
prescriptions for acute pain conditions to a 7-day supply.[18] These
changes in the medico-legal landscape suggest that all prescribers,
including OB/GYNs, will be checking PDMPs more frequently. Of
particular importance forOB/GYNclinical practice, pregnancymay
be the only time awomanwith opioid use disorder or other forms of
SUDengage inmedical treatment,[19]which suggests thatOB/GYNs
are optimally positioned for screenings and interventions.
The delegate model, whereby a prescriber assigns responsibility
for logging in and obtaining reports to another qualified health
professional, for PDMP usage has been demonstrated to be more
cost-effective than prescriber-initiated PDMP query and could
reduce time and resource burden for OB/GYNs.[20] As of 2020, all
states (with the exception of Missouri, which is the only state that
has not yet implemented a statewide PDMP) permit prescriber
delegates to access the PDMP.[3] After resolving workflow issues
regarding PDMP access, however, there is evidence to suggest that
Table 1




Academic/University-affiliated medicine 116 (29.2%)
Private Practice 144 (36.3%)
Hospital-based practice 57 (14.4%)
Federally qualified heath center 16 (4.0%)
Other settings 8 (2.0%)
No response 56 (14.1%)
Level of Training
Attending 241 (60.7%)
Resident physician 62 (15.6%)
Fellow 33 (8.3%)
Other 5 (1.3%)




Prefer not to answer or No response 59 (14.9%)
Currently Registered with the Prescription Drug
Monitoring Program (PDMP)
Yes 308 (77.6%)
No or I cannot access the PDMP 71 (17.9%)
No response 18 (4.5%)








Mandatory PDMP Use 320 (80.6%)
Voluntary PDMP Use 38 (9.6%)
Unknown Practice Location 39 (9.8%)
Mean Years in Practice (SD) 16.14 (12.82)
Last time using the PDMP
Within last week 81 (20.4%)
Within the last month 84 (21.2%)
Within the 6 months 55 (13.9%)
Within the last year 17 (4.3%)
Longer than one year ago 10 (2.5%)
I have never used the PDMP 45 (11.3%)
I cannot access the PDMP 2 (0.5%)
No response 103 (25.9%)
PDMP provides the following information
Prescribed medication type 324 (81.6%)
The quantity of medications dispensed 311 (78.3%)
Name of provider on prescription 281 (70.8%)
The pharmacy dispensing medication 217 (54.7%)
The PDMP will tell me the primary reason why the
medication is prescribed
13 (3.3%)
None of the above 3 (0.8%)
No response 58 (14.6%)
∗
Mandatory use indicates that the OB/GYN practices within a state that requires that the prescriber
query the PDMP prior to initiation of a new controlled substance prescription; whereas voluntary
use indicates that querying the PDMP was not required in the state of practice at the time of data
collection.
Table 2
Obstetrician-Gynecologist (OB/GYN) Perceptions of the Prescrip-
tion Drug Monitoring Program Purpose
∗,†.
Practice Legal Environment







To identify patients who are using
medications that they haven’t disclosed to
their current provider
98 (33.8%) 11 (30.6%)
To identify patients who are “doctor
shopping” for medications
67 (23.1%) 6 (16.7%)
To allow the physician to verify medications
that the patient is being prescribed
111 (38.3%) 19 (52.8%)
Other (please specify) 14 (4.8%) 0 (0.0%)
∗
Missing responses (n=30) were not included in denominators.
† Respondents who did not provide their state location (n=39) were not included.
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physicians are uncertain about how and when to discuss
information gleaned from PDMPs with their patients.[21]
This uncertainty may contribute to decreased perceptions of
PDMP utility.
4.2. Strengths and limitations
This study employed evidence-based practices for maximizing
physician response rates, including the use of multiple, timely



































































































































Figure 1. Obstetrician-Gynecologist (OB/GYN) Estimates of the Proportion of their Patients Suspected of Abusing Opioids (Top) and OB/GYN Reported Reason
for Querying the Prescription Drug Monitoring Program (Bottom), by Practice Legal Environment
∗
.
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trusted professional association (here, ACOG). Despite these
efforts, the response rate to this survey is in line with typical
response rates for web-based surveys to physicians[23] that do not
include financial incentives.[22] An additional limitation is that we
were reliant on self-reported measures of OB/GYN PDMP usage
and were unable to compare these self-reports with patterns of
actual PDMP use.
5. Conclusions
ACOG members are diverse in their perceptions regarding the
utility and purpose of PDMPs; though, the majority agree that
PDMPs are a primary prevention tool for drug abuse and
diversion. However, a knowledge translation gap may still exist-
as only a third of OB/GYNs report checking the PDMP for their
patients with opioid prescriptions. Increased training is needed
regarding clinical utility of PDMPs along with practical guidance
for incorporating the PDMP into OB/GYN practice.
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